# LoQus23 Therapeutics Ltd: Research, London, United Kingdom

> LoQus23 Therapeutics Ltd: LoQus23 Therapeutics Ltd is a biotechnology company based in Cambridge, founded in 2019. Based in London, United Kingdom.

Source: https://millionrounds.com/startup/loqus23-therapeutics-ltd (Millionrounds; every figure on the page links to its filing or article)

United Kingdom · [Research startup](https://millionrounds.com/companies)

# LoQus23 Therapeutics Ltd

LoQus23 Therapeutics Ltd is a biotechnology company based in Cambridge, founded in 2019.

Email

Funding reported Last round: Seed

Research London, United Kingdom

Follow LoQus23 Therapeutics Ltd and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Floqus23-therapeutics-ltd)

Company summary

- **Founded:** 2019 7 years old
- **Team:** 15 11 to 50 people
- **Funding reported:** 46.4M as listed, currency not stated
- **Last round:** Seed Nov 2021

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for LoQus23 Therapeutics Ltd has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About LoQus23 Therapeutics Ltd

LoQus23 Therapeutics Ltd is a biotechnology company based in Cambridge, founded in 2019.

The company focuses on developing oral small molecule inhibitors aimed at halting somatic expansion, which is a key factor in Huntington’s Disease and other triplet repeat expansion disorders. Their mission is to address DNA instability to slow or stop neurodegeneration in these diseases. The company’s lead drug candidate, LQT-23, is a first-in-class oral medication designed to slow or stop the progression of Huntington’s Disease. It is expected to enter clinical trials in 2026. LoQus23 also targets conditions like Myotonic Dystrophy Type 1 and other related disorders. With a strong foundation in research and development, the company collaborates with academic and research institutions to enhance understanding of these diseases and advance therapeutic options.

## What company datasets say LoQus23 Therapeutics Ltd raised

Funding, as reported

Reported in all **46.4M** in the source's currency

Rounds **3**

Last round **Seed**

Last round size **46.2M**

Last round date **Nov 2021**

Investors listed **4**

## Funding filed with regulators

LoQus23 Therapeutics Ltd filed 4 raises, $53M in all. Filings say how much was sold and to how many investors; they never name the investors.

- May 2026 **$20M** UK share allotment
- Sept 2024 **$26M** UK share allotment
- Jul 2023 **$4.3M** UK share allotment
- Feb 2023 **$2.4M** UK share allotment

## Founders and team

From LoQus23 Therapeutics Ltd's own website: 9 on the team.

- **Dr David Reynolds** Chief Executive Officer
- **Dr Caroline Benn** Chief Scientific Officer
- **Dr Amanda Davis** VP of Operations and Development
- **Dr David Hardick** Head of Chemistry
- **Deb Tonge** Finance Director
- **Dr Paulina Marzec** Senior Principal Scientist
- **Dr Pauline Drouhin** Senior Principal Scientist – Medicinal Chemistry
- **Dr William Esmieu** Principal Scientist – Medicinal Chemistry
- **Sarah Richards** Office Manager

## The company, in detail

What they build

Known for

health care dna repair allosteric inhibitors biotechnology research allosteric modulation huntingtons somatic expansion biotech funding genetic evidence small molecule somatic expansion inhibitors triplet repeat diseases allosteric inhibition neurodegeneration slowing structure-based approach neurodegeneration small molecule drugs dna instability

Built with from their website

Google Maps parallax.js WordPress.org Max Mega Menu Viewport Meta Facebook SDK Priority Hints Google Font API MySQL PrimeNG

+8 more

Mobile Friendly jQuery Anthropic Claude RSS Magnific Popup Facebook Social Plugins Lightbox Google Maps (Non Paid Users)

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** England
- **Revenue:** 1M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/loqus23-therapeutics)

## Research in United Kingdom

Startups like it

- [**Isomorphic Labs** London · founded 2021 *Raised*](https://millionrounds.com/company/isomorphic-labs)
- [**Basecamp Research** London · founded 2019 *Raised*](https://millionrounds.com/company/basecamp-research)
- [**Callosum** London · founded 2025 *Raised*](https://millionrounds.com/company/callosum)
- [**Artios** Babraham · founded 2016 *Raised*](https://millionrounds.com/company/artios)
- [**First Light Fusion** Yarnton · founded 2011 *Raised*](https://millionrounds.com/company/first-light-fusion)
- [**IMU Biosciences** London · founded 2019 *Raised*](https://millionrounds.com/company/imu-biosciences)
- [**Orbital Industries** London · founded 2022 *Raised*](https://millionrounds.com/company/orbital-industries)
- [**Genomics** Oxford · founded 2014 *Raised*](https://millionrounds.com/company/genomics)

## Is this your company?

Add your raise, your deck and your story, and put LoQus23 Therapeutics Ltd in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)